Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies (NASDAQ: SINT) has submitted a 510(k) premarket notification to the FDA for its innovative silicon nitride osteotomy wedges, marking its entry into the $750.5 million foot and ankle fusion market. The company's proprietary silicon nitride (Si₃N₄) technology has already been used in over 50,000 spinal interbody fusion devices since 2008.

The new implants offer key advantages including pro-osteogenic properties, antimicrobial capabilities without additives, and superior radiographic clarity. SINTX's solution combines advanced biomaterial science with disposable instrumentation, targeting a market expected to reach $1.38 billion by 2032.

This strategic launch follows SINTX's recent acquisition of SiNAPTIC Surgical on July 1, 2025, positioning the company for significant revenue growth in both hospital and ambulatory surgery center settings.

SINTX Technologies (NASDAQ: SINT) has announced the acquisition of SiNAPTIC Holdings' surgical business assets, marking a strategic move into the $1.3B foot and ankle fusion market. The deal includes six differentiated foot and ankle implant systems, complete with intellectual property and product designs.

The transaction, valued at $750,000 in common shares at $3.465 per share, includes 325,000 performance-based warrants. Key SiNAPTIC executives will join SINTX's leadership team, bringing expertise in product development, regulatory strategy, and commercialization. The global ankle fusion market is projected to grow from $750.5M to $1.38B by 2032, with a 9.1% CAGR.

SINTX Technologies (NASDAQ: SINT), the only FDA-registered producer of implantable silicon nitride, has announced a strategic vision to accelerate commercialization following its February 2025 recapitalization. The company pioneered FDA-cleared silicon nitride implants in 2008, with over 50,000 spinal implants placed worldwide. SINTX holds 18 U.S. patents and 84 pending applications, targeting the $62 billion global orthopedic implant market. Under CEO Eric Olson's leadership, SINTX is developing hybrid biomaterials combining silicon nitride with polymers for spine, oral/maxillofacial, and oncologic reconstruction applications. The company's strategy focuses on joint ventures, IP monetization through licensing, and enhancing AI-supported 3D manufacturing capabilities at its FDA-cleared facility.

SINTX Technologies (NASDAQ: SINT) has announced a strategic transformation from an industrial-ceramics business to a focused medical device innovator, leveraging its silicon nitride technology. The company reported $6.5 million cash on hand as of March 31, 2025, nearly doubled from $3.6 million, bolstered by a $5.0 million private placement in February 2025. SINTX has significantly reduced its operating cash burn from $2.7M to $1.3M year-over-year. The company is streamlining operations through the sale of TA&T subsidiary, shutdown of its Armor subsidiary, and lease liability negotiations. SINTX's strategic focus includes expanding silicon nitride applications in medical markets, including orthopedic implants, spinal fusion devices, dental products, and medical textiles. The company maintains the only FDA-registered and ISO 13485 certified silicon nitride ceramic manufacturing facility.

SINTX Technologies (NASDAQ: SINT) announced significant changes to its Board of Directors as part of its strategic transformation into a focused medical technology business. Key changes include:

- Dr. B. Sonny Bal's retirement as Chairman after serving since 2012
- Appointment of current President and CEO Eric Olson as Chairman of the Board
- Jay Moyes named as Lead Independent Director
- Addition of four new directors:

• Chris Lyons - 35+ years in musculoskeletal and spine markets
• Robert Mitchell - 30+ years in global medical device leadership
• Mark Anderson - 35+ years at Boston Scientific across multiple divisions
• Gregg Honigblum - Chief Strategy Officer with extensive funding experience

The new board brings combined expertise in orthopedics, spine, interventional pain, cardiovascular, medical device business development, and global commercialization.

SINTX Technologies (NASDAQ: SINT) announced the publication of a peer-reviewed study demonstrating the biomechanical advantages of silicon nitride in anterior cervical discectomy and fusion (ACDF) procedures. The research, conducted by SRM Institute of Science and Technology in collaboration with SINTX, compared various cage designs and materials used in cervical spine fusion.

The study highlighted several key advantages of silicon nitride over traditional materials like PEEK and titanium:

• Reduced cage subsidence and exceptional load-bearing capability
• Enhanced stress distribution and lower risk of adjacent segment degeneration
• Superior osseointegration properties compared to biologically inert PEEK
• Better post-surgical imaging capabilities due to radiolucency

With global spinal fusion procedures expected to exceed $10 billion annually, SINTX aims to leverage these findings to expand the adoption of silicon nitride-based medical devices in orthopedic applications.

Sintx Technologies (NASDAQ: SINT) announced a significant leadership transition as Dr. Sonny Bal retires from his position as Chairman of the Board, with CEO Eric Olson unanimously appointed as the new Chairman, effective immediately.

Dr. Bal, who served as Chairman since 2015, will remain on the Board of Directors to ensure continuity. Under his leadership, Sintx underwent transformation in the advanced materials sectors, particularly focusing on high-value medical applications and strategic partnerships.

Eric Olson, who became CEO in August 2024, brings experience in medical device and industrial sectors. His appointment as Chairman aligns with the company's strategy to accelerate commercialization, enhance financial discipline, and explore strategic initiatives including partnerships, licensing, and M&A opportunities.

SINTX Technologies (NASDAQ: SINT) has completed a $5 million private placement with institutional and accredited investors, priced at-the-market under Nasdaq rules. The company issued 1,449,287 shares of common stock at $3.45 per share, along with unregistered warrants to purchase an equal number of shares at $3.32 per share.

The warrants are immediately exercisable and will expire in five and a half years. H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds, after deducting fees and expenses, will be used for working capital purposes.

The securities were offered under Section 4(a)(2) of the Securities Act and Regulation D, exclusively to accredited investors. SINTX has agreed to file registration statements with the SEC for the resale of the common stock and shares issuable upon warrant exercise.

SINTX Technologies (NASDAQ: SINT) has announced the sale of its subsidiary, Technology Assessment and Transfer (TA&T), to Tethon This strategic move aims to streamline operations and focus on the medical device sector, particularly in bioceramic technologies for healthcare applications.

The transaction provides significant financial benefits, reducing corporate liabilities by $750,000 and cutting annual operating expenses by over $1.7 million. The company will concentrate on commercializing its silicon nitride-based technologies, which have been utilized in human implants since 2008.

According to CEO Eric K. Olson, this divestment represents a strategic realignment that will enable SINTX to commit its resources fully to the medical device market, where their advanced ceramics expertise can make the most significant impact.